Effect of Canagliflozin (CANA) on Liver Function Tests (LFTs) in Patients with Type 2 Diabetes Mellitus (T2DM)

被引：0

|

作者：

Usiskin, Keith

Leiter, Lawrence A.

Forst, Thomas

Polidori, David

Xie, John

Sha, Sue

机构：

来源：

DIABETES | 2014年 / 63卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1092-P

引用

收藏

页码：A284 / A284

页数：1

相关论文

共 50 条

[1] Effect of Canagliflozin (CANA) on Liver Function Tests (LFTs) in Patients with Type 2 Diabetes Mellitus (T2DM) and Presumed Liver Fibrosis Suggestive of Nonalcoholic Steatohepatitis (NASH)
Polidori, David
Meininger, Gary
[J]. DIABETES, 2017, 66 : A348 - A348
[2] Changes in Liver Function Tests (LFTs) with Canagliflozin (CANA) vs. Sitagliptin (SITA) in Patients with Type 2 Diabetes Mellitus (T2DM) Are Related to Changes in A1c and Body Weight (BW)
Leiter, Lawrence A.
Forst, Thomas
Polidori, David
Balis, Dainius
Xie, John
Sha, Sue
[J]. DIABETES, 2015, 64 : A328 - A328
[3] Blood Pressure (BP) Effects of Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM)
Pfeifer, Michael
Townsend, Raymond
Davies, Michael J.
Vijapurkar, Ujjwala
Ren, Jimmy
[J]. DIABETES, 2016, 65 : A303 - A303
[4] Genital Mycotic Infections With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM)
Nyirjesy, Paul
Sobel, Jack
Fung, Albert
Gassmann-Mayer, Cristiana
Ways, Kirk
Usiskin, Keith
[J]. DIABETES, 2013, 62 : A276 - A276
[5] Achievement of Diabetes-related Treatment Goals with Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM)
Blonde, Lawrence
Woo, Vincent
Mathieu, Chantal
Yee, Jacqueline
Vijapurkar, Ujjwala
Meininger, Gary
[J]. DIABETES, 2014, 63 : A284 - A284
[6] Pharmacokinetics (PK) and Pharmacodynamics (PD) of Canagliflozin (CANA) in Pediatric Patients with Type 2 Diabetes Mellitus (T2DM)
Tamborlane, William
Polidori, David
Di Prospero, Nicolas
[J]. DIABETES, 2017, 66 : A371 - A371
[7] Canagliflozin (CANA) Reduces Serum Uric Acid (SUA) in Patients with Type 2 Diabetes Mellitus (T2DM)
Davies, Michael
Trujillo, Angelina
Vijapurkar, Ujjwala
Damara-Ju, C. V.
Meininger, Gary
[J]. DIABETES, 2014, 63 : A283 - A284
[8] Consistent Effects of Canagliflozin (CANA) Across Racial Subgroups of Patients with Type 2 Diabetes Mellitus (T2DM)
Gavin, James R., III
Davies, Melanie J.
Davies, Michael
Vija-Purkar, Ujjwala
Alba, Maria
[J]. DIABETES, 2014, 63 : A285 - A285
[9] Urinary Tract Infection (UTI) With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM)
Nicolle, Lindsay E.
Capuano, George
Fung, Albert
Usiskin, Keith
[J]. DIABETES, 2013, 62 : A296 - A296
[10] Lower Blood Pressure (BP) With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM)
Weir, Matthew R.
Januszewicz, Andrzej
Gilbert, Richard
Gonzalez, Fernando Lavalle
Meininger, Gary
[J]. DIABETES, 2013, 62 : A278 - A278

← 1 2 3 4 5 →